Company intelligence / Profile preview

BIOKNOSTIC

Zaragoza, Aragon, Spainconvention.bio.org ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

BIOKNOSTIC has developed a proprietary nanovaccine platform called Nanoparticulated Vaccinex that uses nanoscale carriers and powerful adjuvants to enhance immune responses. The technology aims for more effective, longer-lasting, and safer vaccines that are thermostable and modular. It targets both infectious diseases and cancer indications. No specific clinical trial results are publicly disclosed as of June 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Nanoparticle-based vaccines (nanovaccines)super-adjuvants
Industry: Biotech

Partnerships

Global partnerships referenced for vaccine development/distribution but no specific partners named.

Beyond the preview

Go deeper on BIOKNOSTIC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOKNOSTIC.

Explore the full profile